scholarly journals Reply to: “Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything” and “More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations”

2018 ◽  
Vol 68 (1) ◽  
pp. 219-220 ◽  
Author(s):  
Lauren A. Beste ◽  
Pamela K. Green ◽  
Kristin Berry ◽  
Matthew J. Kogut ◽  
Stephen K. Allison ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Hepatocellular Cancer ◽  
Direct Acting Antiviral ◽  
Timing Of Treatment ◽  
Direct Acting ◽  
Extended Indication

scholarly journals Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy

2020 ◽  
Vol 7 (12) ◽  
Author(s):  
Alicia B Carver ◽  
Autumn D Zuckerman ◽  
Joshua DeClercq ◽  
Leena Choi ◽  
Cody A Chastain
Keyword(s):  
Antiviral Therapy ◽  
Real World ◽  
Sustained Virologic Response ◽  
Response Rates ◽  
Virologic Response ◽  
Direct Acting Antiviral ◽  
Rapid Virologic Response ◽  
Persistent Viremia ◽  
Direct Acting ◽  
High Sustained Virologic Response

Abstract Rates of persistent viremia (PV) while on direct-acting antiviral therapy were low (5.7%) in a real-world cohort of 983 patients. High sustained virologic response rates were achieved both in patients with PV (92.9%) and those with rapid virologic response (96.5%), without significant differences.

Evidence of declining HCV transmission in Australia following scale-up of direct acting antiviral therapy

2020 ◽  
Vol 73 ◽  
pp. S606
Author(s):  
Jisoo Amy Kwon ◽  
Gregory Dore ◽  
Behzad Hajarizadeh ◽  
Rebecca Guy ◽  
Richard T Gray
Keyword(s):  
Antiviral Therapy ◽  
Scale Up ◽  
Direct Acting Antiviral ◽  
Hcv Transmission ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document